This comprehensive course is designed to provide an in-depth exploration of key concepts in pharmacology The curriculum is divided into four modules, each focusing on essential aspects of pharmacological principles life sciences, this course will enhance your knowledge and critical thinking skills in the field of pharmacology

May 2022 " MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today Before joining Inversago, Mr.

March 2022 Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B Clinical Trial " MONTREAL (CANADA) – March 15, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced This 28-day trial will test the pharmacokinetics and safety profile of Inversago’s lead molecule, INV

January 2022 Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker Phase 2 clinical development Metabolic disorders are a global epidemic1 MONTREAL--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the successful completion of the Favorable safety, tolerability and pharmacokinetic results from the trial warrant further investigation

GPCR Ecosystem, with the goal is to bring together GPCR scientists, biotech, and pharma leaders as well

more than 25 years of experience in drug development. have been engaged in GPCR cellular and clinical pharmacology I have participated and initiated methodologies for development of pharmacologically active anti-GPCR have published or contributed in 38 published scientific work mainly in the field of immunology and pharmacology creation of Inoviem scientific in Nov. 2011 by myself we have been regularly working with GPCRs for our pharma

other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma